C12N 2795/00062
By genetic engineering
Official title: by genetic engineering
C12N2795/00062 (By genetic engineering) appears on 3 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 5
- Assignees
- 3
- Inventors
- 7
- Latest grant
- 11 Jan 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 1 |
By publication year.
Recent patents
- Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis11 Jan 2022US 11,219,686 B2The Catholic University of America
- Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, Bacillus anthracis and Yersinia pestis11 Feb 2020US 10,556,002 B2The Catholic University of America
- Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer13 Aug 2013US 8,507,445 B2Board of Regents, The University of Texas System
- Genetically Engineered Bacteriophage3 Nov 2022US 2022/0348886 A1Cytophage Technologies Inc.
- Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis14 May 2020US 2020/0147207 A1The Catholic University of America
- Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis20 Sep 2018US 2018/0264102 A1The Catholic University of America
- Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer5 Jan 2012US 2012/0003152 A1
- Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer8 Jul 2010US 2010/0172864 A1Board of Regents, The University of Texas System
Most cited
By later US patents